Generic Name and Formulations:
Dexrazoxane 250mg, 500mg; per vial; pwd for IV infusion after reconstitution and dilution.
Indications for ZINECARD:
To reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300mg/m2 and will continue to receive doxorubicin therapy to maintain tumor control.
Give by slow IV push or rapid drip IV infusion. Doxorubicin should be administered within 30 minutes after starting Zinecard infusion. Administer in 10:1 ratio (eg, 500mg/m2 Zinecard: 50mg/m2 doxorubicin). Renal impairment (CrCl <40mL/min): reduce ratio to 5:1 (eg, 250mg/m2 Zinecard: 50mg/m2 doxorubicin). Hepatic impairment: may need to reduce doxorubicin dose, therefore Zinecard dose must be reduced (maintaining 10:1 ratio).
Chemotherapy regimens that do not contain an anthracycline.
Not recommended for use with initiation of doxorubicin. Renal or hepatic impairment. Monitor cardiac function and for myelosuppression; obtain CBCs frequently. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.
Inj site pain, myelosuppression, possible secondary malignancies (see literature).
Single-use vial—1 (w. diluent)
- 500mg vials (Qty:3)
- appx. price $1544.00
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- Spiriva Respimat Gains Indication and New Dosage Strength
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- CDC: Novel Lyme Disease Pathogen Discovered
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI